Hybridize Therapeutics - Crunchbase Company Profile & Funding

Overview

Hybridize Therapeutics

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Hybridize Therapeutics

CB Rank

860096

Hybridize’s overarching goal is to help patients overcome untreatable viral diseases.

Founded

obfuscation

Private

Leiden, Zuid-Holland, The Netherlands

1-10

hybridizetherapeutics.com/

Biotechnology

Health Care

Key People

Eline van Beest: Chief Executive Officer
Past Role: Nightbalance, Founder and CEO
Bianca Matthee: Chief Operating Officer
Past Role: ProQR Therapeutics, VP Manufacturing and Production

Details

Operating Status

Active

Company Type

For Profit

Phone Number

+31-617524713

Contact Email

info@hybridizetherapeutics.com

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

HYB_BKV

An antisense oligonucleotide therapy targeting BK virus mRNA to inhibit viral replication in kidney transplant and hematopoietic stem cell transplant patients.

HYB_JCV

An antisense oligonucleotide therapy targeting JC virus mRNA to inhibit viral replication and prevent neurological damage in immunocompromised patients.